| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1009141938 |
| P356 | DOI | 10.1038/CDDIS.2013.400 |
| P932 | PMC publication ID | 3920959 |
| P698 | PubMed publication ID | 24136231 |
| P5875 | ResearchGate publication ID | 258055930 |
| P50 | author | Eugene S Kim | Q90707464 |
| Jed G Nuchtern | Q125346872 | ||
| P2093 | author name string | Y Zhao | |
| H Zhang | |||
| J Cheng | |||
| J Yang | |||
| Y Yu | |||
| Y Rojas | |||
| R H Patel | |||
| J Dou | |||
| I T Ma | |||
| J M Shohet | |||
| S A Vasudevan | |||
| Y-H Fan | |||
| P2860 | cites work | The p53 pathway as a target in cancer therapeutics: obstacles and promise | Q27690770 |
| A dynamic role of HAUSP in the p53-Mdm2 pathway | Q28253645 | ||
| Targeting ubiquitin specific proteases for drug discovery | Q28254834 | ||
| Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 | Q29614430 | ||
| Modes of p53 regulation | Q29615657 | ||
| Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 | Q29617850 | ||
| p53 and human cancer: the first ten thousand mutations. | Q33767112 | ||
| Inactivation of HAUSP in vivo modulates p53 function | Q33802926 | ||
| The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor | Q34030117 | ||
| MDM2, MDMX and p53 in oncogenesis and cancer therapy | Q34166049 | ||
| Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme | Q34240760 | ||
| p53 post-translational modification: deregulated in tumorigenesis | Q34300569 | ||
| Conformational stabilization of ubiquitin yields potent and selective inhibitors of USP7. | Q34487783 | ||
| The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification | Q35184984 | ||
| The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. | Q35773674 | ||
| Promoting apoptosis as a strategy for cancer drug discovery | Q36292878 | ||
| A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance | Q36338365 | ||
| The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans | Q36509629 | ||
| Deubiquitinating enzymes as novel anticancer targets | Q36536984 | ||
| Immunology and immunotherapy of neuroblastoma | Q36856798 | ||
| The genetic landscape of high-risk neuroblastoma | Q36929803 | ||
| TAK1 inhibitor 5Z-7-oxozeaenol sensitizes neuroblastoma to chemotherapy | Q37185105 | ||
| Tumor suppressive functions of p53 | Q37412688 | ||
| Tumour suppression by p53: a role for the DNA damage response? | Q37591937 | ||
| Reactivation of p53: from peptides to small molecules. | Q37818922 | ||
| Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma | Q37940719 | ||
| Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes | Q39437160 | ||
| Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma | Q39560187 | ||
| Nutlin-3a is a potential therapeutic for ewing sarcoma | Q39628701 | ||
| Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells | Q39813804 | ||
| Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma | Q40155261 | ||
| Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell line | Q40175009 | ||
| Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells | Q40410781 | ||
| SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. | Q40868752 | ||
| Mdm2 association with p53 targets its ubiquitination | Q42824389 | ||
| MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death | Q45862563 | ||
| Long-term complications in survivors of advanced stage neuroblastoma. | Q50474808 | ||
| A developmental model of neuroblastoma: differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage. | Q52199250 | ||
| Neuroblastoma | Q54265665 | ||
| Recent advances in neuroblastoma | Q56637924 | ||
| Low frequency of the p53 gene mutations in neuroblastoma | Q72496549 | ||
| The loss of mdm2 induces p53-mediated apoptosis | Q73673966 | ||
| Preclinical models of pediatric solid tumors (neuroblastoma) and their use in drug discovery | Q84970191 | ||
| P921 | main subject | apoptotic process | Q14599311 |
| neuroblastoma | Q938205 | ||
| P304 | page(s) | e867 | |
| P577 | publication date | 2013-10-17 | |
| P1433 | published in | Cell Death and Disease | Q2197222 |
| P1476 | title | USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis | |
| P478 | volume | 4 |
| Q51658298 | (1)H, (13)C and (15)N backbone resonance assignment for the 40.5 kDa catalytic domain of Ubiquitin Specific Protease 7 (USP7). |
| Q37620709 | A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways |
| Q47306770 | A transcriptomic insight into the impacts of mast cells in lung, breast, and colon cancers |
| Q47135501 | Active site-targeted covalent irreversible inhibitors of USP7 impair the functions of Foxp3+ T-regulatory cells by promoting ubiquitination of Tip60. |
| Q46916073 | An inhibitor of the proteasomal deubiquitinating enzyme USP14 induces tau elimination in cultured neurons |
| Q36231919 | Anti-tumoral effect of desmethylclomipramine in lung cancer stem cells. |
| Q54957789 | Clinical Significance of Ubiquitin Specific Protease 7 (USP7) in Predicting Prognosis of Hepatocellular Carcinoma and its Functional Mechanisms. |
| Q38620223 | Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson's Disease |
| Q38336126 | DUBs, the regulation of cell identity and disease |
| Q38695071 | Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint |
| Q64083300 | Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin-induced apoptosis |
| Q38326071 | Deubiquitinases and the new therapeutic opportunities offered to cancer |
| Q28069021 | Deubiquitinases: Novel Therapeutic Targets in Immune Surveillance? |
| Q90088711 | Deubiquitinases: Pro-oncogenic Activity and Therapeutic Targeting in Blood Malignancies |
| Q27026189 | Deubiquitinating enzymes as oncotargets |
| Q48265884 | Deubiquitylating enzymes and drug discovery: emerging opportunities. |
| Q37514045 | Downregulation of RNF128 Predicts Progression and Poor Prognosis in Patients with Urothelial Carcinoma of the Upper Tract and Urinary Bladder |
| Q38565252 | How Does p73 Cause Neuronal Defects? |
| Q28082497 | Inhibition of 19S proteasome-associated deubiquitinases by metal-containing compounds |
| Q47716589 | Inhibition of USP10 induces degradation of oncogenic FLT3. |
| Q89739763 | Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity |
| Q57490982 | Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy |
| Q28075457 | Modulation of the p53/MDM2 interplay by HAUSP inhibitors |
| Q47633676 | Molecular basis of USP7 inhibition by selective small-molecule inhibitors |
| Q36022258 | NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis |
| Q37696208 | Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma |
| Q92529034 | Nuclear deubiquitination in the spotlight: the multifaceted nature of USP7 biology in disease |
| Q92143470 | Oridonin induces Mdm2-p60 to promote p53-mediated apoptosis and cell cycle arrest in neuroblastoma |
| Q61448489 | Pharmacological inhibition of USP7 promotes antitumor immunity and contributes to colon cancer therapy |
| Q38725385 | Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors |
| Q26770579 | Regulation of Mutant p53 Protein Expression |
| Q38252591 | Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities |
| Q37689041 | Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis |
| Q38181181 | Selective and reversible inhibitors of ubiquitin-specific protease 7: a patent evaluation (WO2013030218). |
| Q90505741 | Small molecules that target the ubiquitin system |
| Q36951802 | Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis |
| Q35149652 | TAp73 promotes anabolism |
| Q34774270 | TAp73 promotes anti-senescence-anabolism not proliferation |
| Q36182254 | TAp73 transcriptionally represses BNIP3 expression. |
| Q92002855 | Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet? |
| Q44948244 | Targeting deubiquitinating enzymes in cancer stem cells |
| Q33761920 | The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells. |
| Q42016261 | The p53 tetramer shows an induced-fit interaction of the C-terminal domain with the DNA-binding domain |
| Q41056246 | Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones |
| Q38364665 | Therapeutic opportunities within the DNA damage response |
| Q55361439 | USP49 participates in the DNA damage response by forming a positive feedback loop with p53. |
| Q61816131 | USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia |
| Q98771728 | USP7 Is a Master Regulator of Genome Stability |
| Q47149840 | USP7 Is a Tumor-Specific WNT Activator for APC-Mutated Colorectal Cancer by Mediating β-Catenin Deubiquitination |
| Q100516145 | USP7 mediates pathological hepatic de novo lipogenesis through promoting stabilization and transcription of ZNF638 |
| Q89737230 | USP7 stabilizes EZH2 and enhances cancer malignant progression |
| Q51665623 | USP7/HAUSP: A SUMO deubiquitinase at the heart of DNA replication. |
| Q38262067 | Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer |
| Q89456204 | Ubiquitin-specific protease 7 is a drug-able target that promotes hepatocellular carcinoma and chemoresistance |
| Q37518896 | Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis. |
| Q36121394 | mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling |
| Q91701515 | p53 modifications: exquisite decorations of the powerful guardian |
| Q33576855 | p63 transcriptionally regulates the expression of matrix metallopeptidase 13. |
Search more.